![2-(1-(ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile](/upload/8820/2-1-ethylsulfonyl-3-4-7-2-trimethylsilyl-ethoxy-methyl-7h-pyrrolo-2-3-d-pyrimidin-4-yl-1h-pyrazol-1-yl-azetidin-3-yl-acetonitrile-582794.webp "2-(1-(ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile")
2-(1-(Ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile serves as a pivotal synthetic intermediate and pharmaceutical impurity in the industrial manufacturing process of baricitinib (Olumiant®), a selective and orally bioactive inhibitor of Janus kinase 1 (JAK1) and JAK2 approved by the FDA for the treatment of rheumatoid arthritis, atopic dermatitis, and alopecia areata. As a fully assembled advanced intermediate, 2-(1-(Ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile represents the penultimate stage before final SEM deprotection, and its efficient synthesis has been the subject of dedicated green chemistry and scale-up process development. In quality control contexts, 2-(1-(Ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile is officially recognized under multiple impurity designations — including Baricitinib Impurity 18, Baricitinib Impurity 6, and Baricitinib Impurity 29 — reflecting its status as a process-related substance that must be monitored and controlled in baricitinib drug substance during regulatory filing and commercial production. The compound‘s fully characterized structure and well-defined chemical properties make 2-(1-(Ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile an essential reference standard for analytical method development, method validation (AMV), quality control (QC) applications, Abbreviated New Drug Application (ANDA) filings, and commercial production of baricitinib.
![2-(1-(ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile](/upload/8820/image/20260605/2--1--ethylsulfonyl--3--4--7---2--trimethylsilyl-ethoxy-methyl--7h-pyrrolo-2-3-d-pyrimidin-4-yl--1h-pyrazol-1-yl-azetidin-3-yl-acetonitrile1-919334.webp)
|
Parameter |
Specification |
|
CAS Number |
1187594-13-3 |
|
Molecular Formula |
C₂₂H₃₁N₇O₃SSi |
|
Molecular Weight |
501.68 g/mol |
|
Purity |
≥95% (reference standard grade); ≥98% (upon request) |
|
Physical Form |
Solid |
|
Appearance |
White to off-white to pale yellow solid |
|
Boiling Point |
696.8 ± 65.0 °C (Predicted) |
|
Density |
1.30 ± 0.1 g/cm³ (Predicted) |
|
pKa |
3.70 ± 0.30 (Predicted) |
|
LogP |
2.88 (Predicted) |
|
Solubility |
Soluble in DMSO, DMF, methanol, acetonitrile |
|
Storage Condition |
Sealed, 2–8°C, dry, protected from light, under inert atmosphere |
|
Advantage |
Detail |
|
Production Strength |
GMP-certified campus spanning 100+ mu, 3 multi-purpose workshops, 6 D-grade clean zone production lines, and 150+ reactors (20L–5000L), supporting high/low temp, anaerobic & hydrogenation; kg to ton scale production. |
|
Fast Delivery |
R&D samples: one week; commercial orders: 1–2 months after payment. Express (DHL/FedEx) or air/sea freight available. |
|
Global Partners |
Trusted by 30+ pharmaceutical companies in USA, Europe, India, Brazil, and Southeast Asia; long-term cooperation with generic drug manufacturers, CROs, and impurity standard distributors. |
|
Licensed Exporter |
Valid drug import/export license — no compliance delays. |
|
Dual Quality Grades |
Both research/pharma grade（≥98%）and high-purity impurity grade（≥99%）available to meet diverse customer needs. |
Each batch undergoes:
● Gas chromatography (GC) – purity ≥97.0%
● Non‑aqueous titration – purity ≥97.0%
● Refractive index – confirmatory analysis
● ¹H NMR – structural verification
● Appearance – colorless to light yellow to light orange clear liquid
A comprehensive COA, MSDS (with full GHS information), and certificate of origin accompany every shipment.
A: This compound is recognized across the impurity landscape under several designations: Baricitinib Impurity 18, Baricitinib Impurity 6, Baricitinib Impurity 29, and Baricitinib Sulfonyl Impurity. One reference standard, multiple designation entries — allowing you to qualify once and use across multiple regulatory and QC contexts.
A: Under recommended storage conditions (sealed, 2–8°C, dry, protected from light, under inert atmosphere), 2-(1-(Ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile has a shelf life of 2 years from the date of manufacture. Stability study data supporting this shelf life claim is available upon request.
Sourcing 2-(1-(Ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile for your baricitinib impurity profiling program should be straightforward. Cosperpharm simplifies the process.
Address
No. 2 Yangguang 3rd Road, Duodao Chemical Cycle Industrial Park, Jingmen City, Hubei Province, China
Tel
![N-[2-(Dodecyldisulfanyl)ethyl]acrylamide](/upload/8820/n-2-dodecyldisulfanyl-ethyl-acrylamide-913889.webp "N-[2-(Dodecyldisulfanyl)ethyl]acrylamide")
![Heptanoic acid, 7-[(4-hydroxybutyl)amino]-, 1-hexylnonyl ester](/upload/8820/heptanoic-acid-7-4-hydroxybutyl-amino-1-hexylnonyl-ester-832597.webp "Heptanoic acid, 7-[(4-hydroxybutyl)amino]-, 1-hexylnonyl ester")
